SCHEMBL6241981

SCHEMBL6241981

CCCS(=O)(=O)NC1CCCC=C1c1ccc(-c2ccc(C#N)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 10/20 0.46
CYP11B1 P15538 8/20 0.46
GRIA2 P42262 3/20 0.37
KCNH2 Q12809 2/20 0.37
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
GRIA4 P48058 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
HSD11B1 P28845 1/20 0.34
PTGS2 P35354 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA3 P42263 1/20 0.34
PGR P06401 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242835 0.93 CYP11B1 (0.43) CYP11B2CYP11B1GRIA2KCNH2PSEN1
SCHEMBL6246324 0.86 PSEN1 (0.43) CYP11B2CYP11B1KCNH2PSEN1PSEN2
SCHEMBL6241141 0.85 CYP11B1 (0.35) CYP11B2CYP11B1PSEN1PSEN2APH1B
SCHEMBL6237481 0.83 CYP11B1 (0.39) CYP11B2CYP11B1PSEN1PSEN2APH1B
SCHEMBL6236867 0.83 ADAMTS4 (0.40) CYP11B2CYP11B1HRH3PGR
SCHEMBL6240184 0.82 CYP11B1 (0.39) CYP11B2CYP11B1PSEN1PSEN2APH1B
SCHEMBL6241979 0.81 GRIA4 (0.51) CYP11B2CYP11B1GRIA2KCNH2GRIA4
SCHEMBL6239570 0.81 ADAMTS4 (0.43) CYP11B2CYP11B1KCNH2
SCHEMBL6242093 0.79 CYP11B1 (0.35) CYP11B2CYP11B1PSEN1PSEN2APH1B
SCHEMBL6244084 0.79 CA12 (0.38) CYP11B2CYP11B1KCNH2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 CYP11B2 339/4885CYP11B1 444/4885GRIA2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.